Sök
TM & Partners has advised Vivesto AB in connection with its fully secured rights issue of shares. Through the rights issue, the company will receive proceeds of approximately SEK 53.8 million before transaction costs.

Vivesto is a Swedish development company that aims to offer new treatment options for difficult‑to‑treat forms of cancer where there are significant medical needs and considerable market potential. Vivesto’s shares are admitted to trading on Nasdaq Stockholm.

TM & Partners’ team consisted of:
Johan Wigh (Partner)
Philip Bihl (Senior Associate)
Emma Ström (Associate)

TM & Partners is a leading Swedish law firm with a focus on transaction advice and commercial law.

For more information, please contact:
Johan Wigh
E-mail: johan.wigh@tmpartners.se
Phone: + 46 76 00 283 26

TM & Partners has assisted the sellers in connection with Cambio Healthcare Systems AB’s acquisition of LeapScribe Sverige AB. Cambio is one of the Nordic region’s leading providers of digital solutions for healthcare. LeapScribe is a Swedish technology and innovation company founded by healthcare professionals, innovators and engineers and is developing an AI driven digital service for automated medical documentation in healthcare.

For more information regarding the acquisition, please see the following link:
https://www.cambiogroup.com/cambio-acquires-leapscribe-an-ambient-scribe-company/

Our team consisted of:
Sten Hedbäck (partner, M&A)
Mikael Ahlberg (counsel, M&A)

For more information, please contact:
Sten Hedbäck
Phone: 076-00 283 05
Email: sten.hedback@tmpartners.se

TM & Partners has advised Healthy to 100 AS in connection with a reverse takeover through which eBlitz Group AB has acquired all shares in the Norwegian company Healthy to 100 AS in exchange for newly issued shares in eBlitz Group, whereafter the company’s operations essentially consist of the operations of Healthy to 100. In connection with the transaction, the company name of eBlitz Group has been changed to H100 Group AB, whose shares are still listed on Nordic SME after the acquisition.

H100 Group AB is a health technology company operating in the health and longevity industry. The company’s business idea is to support providers of health and lifestyle services through AI-powered automation, digital growth tools, and integrated platform solutions, with the goal of helping people live healthy lives to 100 and beyond.

Our team consisted of:
Johan Wigh (Partner)
Hanna Hillgren (Senior Associate)
Jacob Elovsson Hultin (Senior Associate)

For more information, please contact Johan Wigh
E-mail: johan.wigh@tmpartners.se
Phone: 076-00 283 26

TM & Partners has advised NextCell Pharma AB (publ) in connection with its rights issue of units, consisting of shares and warrants, of approximately SEK 40 million. In the event of full utilization of all outstanding warrants, the company can receive additionally a maximum of approximately SEK 113 million.

NextCell is a cell therapy company that is in phase 2 studies with the drug candidate ProTrans for the treatment of type 1 diabetes. NextCell owns Cellaviva, the largest stem cell bank in the Nordics and QVance, a quality analysis CRO company in start up. NextCell’s shares are admitted to trading on Nasdaq First North Growth Market.

Our team consisted of:
Johan Wigh (Partner)
Jacob Elovsson Hultin (Associate)
Philip Bihl (Associate)

For more information, please contact Johan Wigh:
E-mail: johan.wigh@tmpartners.se
Phone: +46 76 00 283 26

We advised Team Olivia in connection with the sale of Team Olivia’s Norwegian operation to Humana. The operation, which in the transaction is valued at SEK 341 million on a cash and debt free basis, provides services to appr. 1,000 customers and employs appr. 2,000 employees, with annual sales of appr. SEK 910 million.

The transaction is subject to customary conditions and approvals and is expected to close in Q2 2024.

Team Olivia’s main owner is Procuritas Capital Investors IV GP Ltd.

Our team consists of:

For more information, please contact Sten Hedbäck:
E-post: sten.hedback@tmpartners.se
Tel: +46 76 00 283 05

We have assisted Norvestor’s portfolio company NetNordic, a Nordic system integrator specialized in solutions and services within Network, Security, Cloud and Collaboration, in connection with the acquisition of Gohybrid in October 2023 and the acquisition of EdgeGuide in January 2024.

Our team consisted of:

 

We advise Team Olivia in connection with the sale of Team Olivia’s Swedish care division, including the operations within Individual & Family and Home Care business, to Attendo. The division, which in the transaction is valued at SEK 950 million on a cash and debt free basis, includes appr. 120 care units with close to 3,000 employees, with annual sales of appr. SEK 1,350 million.

The transaction is subject to customary conditions and approvals and is expected to close in the beginning of 2024.

Team Olivia’s main owner is Procuritas Capital Investors IV GP Ltd.

Our team consists of:

For more information, please contact Sten Hedbäck:
E-post: sten.hedback@tmpartners.se
Tel: +46 76 00 283 05

TM & Partners has advised a Swedish fiber infrastructure company on drafting several key customer framework agreements regarding the use of the client’s long-haul dark fibre infrastructure in Northern Europe and related services.

TM & Partners’ team comprised of :

We have advised a Swedish industrial company on an agreement regarding an IT solution that uses Artificial Intelligence (AI) for real time analytics. The agreement was signed in January 2023 and is part of the client’s strategic investment in IT security.

TM & Partners’ team comprised of :

TM & Partners has served as Swedish legal counsel to Veranex Inc in connection with the acquisition of Devicia AB and Clarvin AB together with their affiliated companies Kickfile AB, Lea Group AB och Limulus Bio AB. The acquired companies are a portfolio of full-service medical device consultancy companies, providing regulatory and clinical affairs, quality assurance, and biocompatibility services for medical devices and in vitro diagnostic (IVD) devices.

Veranex is a global tech-enabled service provider dedicated to the medical technology industry.

TM & Partners team was led by:

and also included:

Read more about Veranex here

Cookie policy
TM & Partners

This website uses cookies in order to perform certain services and to help you as a user to navigate the site in an efficient manner. A cookie is a text file containing a small amount of information that is stored on your device provided your consent. For more information, please refer to Cookie Policy.

Necessary Cookies

Cookies necessary for remembering your cookie-preferences.

Performance cookies

Performance cookies are cookies used specifically for gathering data on how visitors use a website, which pages of a website are visited most often, or if they get error messages on web pages. These cookies monitor only the performance of the site as the user interacts with it. These cookies do not collect identifiable information on visitors, which means all the data collected is anonymous and only used to improve the functionality of a website.